COMPASS Pathways co-founder Ekaterina Malievskaia steps down as Chief Innovation Officer, remains on board

COMPASS Pathways plc

Dr. Malievskaia will step down as Chief Innovation Officer effective June 16, 2023, by mutual agreement.
She will remain a non-executive director, Class I, with term expiring at 2024 annual meeting.
Executive responsibilities will be assumed by the existing executive team.
She co-founded COMPASS in 2017 and led the phase 2b trial of COMP360 psilocybin for treatment-resistant depression.
Transitioning to non-executive director, she will receive annual cash retainer of $40,000 and equity awards.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Dr. Ekaterina Malievskaia

Chief Innovation Officer

CMPS · COMPASS Pathways plc

Effective: 2023-06-16
Filed: May 31, 2023, 7:59 PM ET

Dr. Malievskaia will step down from her executive role and that her employment agreement will terminate effective June 16, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Ekaterina Malievskaia changed role as Chief Innovation Officer at COMPASS Pathways plc.

Action: stepped down
Role: Chief Innovation Officer

Exact text from the filing

Dr. Malievskaia will step down from her executive role and that her employment agreement will terminate effective June 16, 2023

View on SEC.gov

COMPASS Pathways plc filing history →

Source: SEC EDGAR

accession 0001816590-23-000072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.